GlassScriptPhysician profile
Farzad Forohar
NPI 1285603746
$8,463.49
in general payments reported to CMS, 2019-2025
22 companies · $985 in 2025
The $985 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2021: $125 · 2022: $149 · 2023: $5,107 · 2024: $1,915 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,003 · Food and Beverage: $2,572 · Travel and Lodging: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,002.78 |
| Food and Beverage | $2,572.14 |
| Travel and Lodging | $431.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $5,032.47 | 2023-2025 | Evis Exera III Gastrointestinal Videoscope, Evis Exera Lll Colonovideoscope, Single Use Electrosurgical Snare Sd-400 |
| Abbvie INC. | $593.29 | 2019-2025 | |
| Apollo Endosurgery US INC | $581.00 | 2023 | Overstitch Endoscopic Suturing System |
| Madrigal Pharmaceuticals | $456.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Steris Corporation | $390.24 | 2024 | |
| Boston Scientific Corporation | $313.90 | 2023-2025 | Apollo Esg System, Axios |
| Novo Nordisk INC | $176.67 | 2025 | Wegovy |
| Medtronic, INC. | $144.13 | 2024 | Endoflip |
| Intercept Pharmaceuticals, INC. | $129.07 | 2022 | |
| Merck Sharp & Dohme LLC | $124.96 | 2019 | |
| Enterra Medical, INC. | $116.92 | 2024 | |
| Pfizer INC. | $96.00 | 2024-2025 | |
| Endogastric Solutions, INC | $54.67 | 2024 | Esophyx |
| Ipsen Biopharmaceuticals, INC | $48.06 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $32.28 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $32.03 | 2019-2022 | |
| Orphalan INC | $28.02 | 2024 | Cuvrior |
| Alnylam Pharmaceuticals INC. | $25.88 | 2024 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $24.90 | 2024 | Eohilia |
| Ferring Pharmaceuticals INC. | $24.41 | 2019 | |
| Ardelyx, INC. | $20.60 | 2023 | Ibsrela |
| Echosens North America, INC. | $17.00 | 2023 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzad Forohar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.